Search - tctmd.com

Displaying 1 - 20 of 22

Sort: Relevancy | Date

PARACHUTE-HF: Sacubitril/Valsartan Effective in Neglected Chagas Cardiomyopathy

News Conference News ESC 2025

PARACHUTE-HF: Sacubitril/Valsartan Effective in Neglected Chagas Cardiomyopathy

Michael O'Riordan

September 01, 2025

MAPLE-HCM Is a Win, ODYSSEY-HCM Isn’t: Obstructive vs Nonobstructive Divide

News Conference News ESC 2025

MAPLE-HCM Is a Win, ODYSSEY-HCM Isn’t: Obstructive vs Nonobstructive Divide

August 30, 2025

Top Heart Failure News of 2024

News Daily News

Top Heart Failure News of 2024

December 31, 2024

New HCM Guidelines Focus on Cardiac Myosin Inhibitors and Exercise

News Daily News

New HCM Guidelines Focus on Cardiac Myosin Inhibitors and Exercise

Yael L. Maxwell

May 08, 2024

IMPROVE-HCM: Ninerafaxstat May Fill a Niche in Nonobstructive HCM

News Conference News ACC 2024

IMPROVE-HCM: Ninerafaxstat May Fill a Niche in Nonobstructive HCM

April 15, 2024

Ultralow-Temperature Cryoablation Promising for Monomorphic VT

News Conference News EHRA 2024

Ultralow-Temperature Cryoablation Promising for Monomorphic VT

April 12, 2024

Aficamten Delivers Positive Results in SEQUOIA-HCM

News Daily News

Aficamten Delivers Positive Results in SEQUOIA-HCM

December 27, 2023

Could Copper Chelation Benefit HFrEF? TRACER-HF Offers Mixed Clues

News Conference News ESC Heart Failure 2023

Could Copper Chelation Benefit HFrEF? TRACER-HF Offers Mixed Clues

May 25, 2023

Top Heart Failure News of 2022

News Daily News

Top Heart Failure News of 2022

January 04, 2023

Aficamten Safe, Effective for Up to 6 months in Obstructive HCM: REDWOOD-HCM OLE

News Conference News ESC Heart Failure 2022

Aficamten Safe, Effective for Up to 6 Months in Obstructive HCM: REDWOOD-HCM OLE

May 31, 2022

Mavacamten Yields Stable Benefits in Obstructive HCM Over Longer Term

News Conference News ACC 2022

Mavacamten Yields Stable Benefits in Obstructive HCM Over Longer Term

April 03, 2022

In the US, HF Prevalence—and Costs—Rising Steeply: HFSA Report

News Daily News

In the US, HF Prevalence—and Costs—Rising Steeply: HFSA Report

Michael O'Riordan

January 27, 2022

Trial of Cell Therapy for HF Misses Primary Endpoint, but Signals a Path Forward

News Conference News

Trial of Cell Therapy for HF Misses Primary Endpoint, but Signals a Path Forward

November 16, 2021

AHA’s 2020 Top 10: ISCHEMIA, HCM, Early A-fib Intervention, and More

News Daily News

AHA’s 2020 Top 10: ISCHEMIA, HCM, Early A-fib Intervention, and More

December 17, 2020

Missed by Risk Calculators, Few Young MI Patients Were Previously on Statins

News Conference News AHA 2017

Missed by Risk Calculators, Few Young MI Patients Were Previously on Statins

November 14, 2017

Simplified MRI Imaging Tests May Help ID Kids at High CV Risk During Sports

News Conference News ACC 2017

Simplified MRI Imaging Tests May Help ID Kids at High CV Risk During Sports

Michael O'Riordan

March 24, 2017

News Daily News

基因检测不一定是 HCM 诊断的最后一根稻草

Yael L. Maxwell

August 23, 2016

News Daily News

Las Pruebas Genéticas No son Necesariamente la Prueba Concluyente en el Diagnóstico de la CMH

Yael L. Maxwell

August 23, 2016

News Daily News

Genetic Testing Not Necessarily the Nail in the Coffin for HCM Diagnosis

Yael L. Maxwell

August 23, 2016

News Daily News

Survival After Septal Ablation for HOCM Similar to General Population

February 06, 2014

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.